Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trio Rho guanine nucleotide exchange factor (TRIO)
- Target
- TRIO
- Molecular classification
- Enzyme (specifically, a Rho family GEF—a subclass of enzymes that regulate small GTPases), Scaffold protein (due to its multi-domain structure and ability to mediate protein-protein interactions)
01
Overview
Trio Rho guanine nucleotide exchange factor is a large multidomain protein containing two Dbl homology-pleckstrin homology (DH-PH) GEF units (GEFD1 and GEFD2) and a serine/threonine kinase domain. The N-terminal GEF unit activates Rac1 and RhoG, while the C-terminal unit activates RhoA. Trio regulates fundamental processes such as cell adhesion, actin cytoskeleton remodeling, neuronal development, and migration. Its expression is ubiquitous, though altered levels are associated with cancer and neurodevelopmental syndromes. Trio is an essential gene for embryonic development, particularly for proper nervous system formation. Its multi-domain structure makes it a key signaling scaffold, and it is regulated by complex protein-protein interactions and accessory domains.
- Other names
- Triple functional domain proteinARHGEF23PTPRF-interacting proteinMEBASMRD44MRD63tgattriple functional domain proteintriple functional domain (PTPRF interacting)Trio
02
Mechanism of action
Inhibition of GEF activity (blocking GDP-GTP exchange on Rac1, RhoG, RhoA to regulate downstream signaling) and downregulation of actin cytoskeleton-driven processes (e.g., cell migration, invasion).
03
Biological functions
Signal transduction (activates Rho family GTPases, key messengers in cell signaling)Actin cytoskeleton remodeling (critical for cell migration, adhesion, morphogenesis, and axon guidance)Neuronal development and differentiationCell adhesionCell migration and invasion
04
Disease associations
Cancer (overexpressed in several tumor types and implicated in oncogenesis, notably in uveal melanoma)Neurodevelopmental disorders (linked to mutations causing intellectual disability syndromes, e.g., MRD44, MRD63)Inflammation (regulates leukocyte migration and endothelial function)
05
Safety considerations
Off-target effects due to GEF homology and conserved domainsNeurological and developmental functions complicate therapeutic targeting
06
Interacting drugs
ITX3 (small molecule inhibitor targeting Trio's GEF1 domain, used in research)
1 more in the full profile.
07
Biomarkers
Trio expression levels in tumors (potentially relevant as a cancer biomarker)Trio mutation status for developmental disorders
Beyond the preview
Go deeper on Trio Rho guanine nucleotide exchange factor (TRIO).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trio Rho guanine nucleotide exchange factor (TRIO).